Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications

Nur Rahadiani, Jun ichiro Ikeda, Suhana Mamat, Shinya Matsuzaki, Yutaka Ueda, Reina Umehara, Tian Tian, Yi Wang, Takayuki Enomoto, Tadashi Kimura, Katsuyuki Aozasa, Eiichi Morii

Research output: Contribution to journalArticlepeer-review

74 Citations (Scopus)


Aldehyde dehydrogenase 1 (ALDH1) is expressed in stem/progenitor cells, including cancer-initiating cells (CIC) of various organs. In the present study, ALDH1 expression was immunohistochemically examined in uterine endometrioid adenocarcinoma. The ALDH1 was expressed in a small portion of tumor cells, and these ALDH1-expressing cells were less mature than ALDH1-non-expressing cells. The ALDH1-expressing (ALDH1-hi) cells were more tumorigenic, resistant to anti-cancer agents and more invasive than ALDH1-lo cells. Culture of the sorted ALDH1-hi cells yielded both ALDH1-hi and ALDH1-lo cells, whereas ALDH1-lo cells yielded ALDH-lo cells alone. Clinically, a high-level of ALDH1 expression in tumor cells was correlated with T category, lymphatic invasion, recurrence and prognosis of patients. Patients with high ALDH1 expression showed poorer prognoses than those with low expression (P=0.015 for disease-free survival [DFS] and P=0.010 for overall survival [OS]), and high ALDH1 expression was an independent factor for poor prognosis. Aldehyde dehydrogenase 1 is a candidate for CIC marker for uterine endometrioid adenocarcinoma.

Original languageEnglish
Pages (from-to)903-908
Number of pages6
JournalCancer Science
Issue number4
Publication statusPublished - 1 Apr 2011


Dive into the research topics of 'Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications'. Together they form a unique fingerprint.

Cite this